Astrazeneca Pharma India Q1 FY26 Share Price & Earnings Call Analysis
- Market cap
- ₹15,748 Cr
- P/E
- 90.77
- ROE
- 23.29%
- PEG
- 6.11
- Price to sales
- 6.46
- Debt to equity
- 0.13
- 52W high / low
- ₹9,828 / ₹5,720
- Sales growth (5Y)
- 22.84%
- EBITDA margin
- 9.45%
- Net profit margin
- 8.41%
- Promoter holding
- 75.00%
- Sales (last year)
- ₹2,432 Cr
AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.[1]
Guidance scorecard · Q1 FY26 call
What Astrazeneca Phar's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ1 FY26 call
20–40%- AstraZeneca Pharma India expects robust future growth driven primarily by oncology and biopharmaceutical portfolios.
- Company plans multiple new product launches over the coming years, including rare disease products like Soliris.
- The rare disease segment is an emerging focus area, aiming to build awareness and diagnosis capabilities in India, with potential to represent 15-16% of sales globally.
- Growth in oncology has been phenomenal, with cancer portfolio currently constituting around 70%-75% of sales; diversification efforts are ongoing to balance this.
- Revenue growth recorded was 32% in FY 2024-25; management is confident in sustaining high growth, with aspirations to double turnover every two years leading up to 2030.
- AstraZeneca India aims to become a billion-dollar company by 2030, contributing about 1% of the global portfolio.
2 more points from Astrazeneca Phar's call on revenue
Create a free account to keep reading this call
MarginsQ1 FY26 call
FlatSee what Astrazeneca Phar said on margins — free account, 30 seconds.
CapexQ1 FY26 call
Planned- The Company continues to evaluate investments needed in India periodically.
- As a global company committed to India, AstraZeneca plans to make the right level of CAPEX investments over the next several years aligned with its plans for India.
- There is a focus on supporting growth through activities like marketing, medical personnel, and logistics, which impact costs.
- Investment in clinical trials, especially Phase IV trials for new product launches, is ongoing.
FundraisingQ1 FY26 call
See what Astrazeneca Phar said on fundraising — free account, 30 seconds.
Order bookQ1 FY26 call
RisingAsk what Astrazeneca Phar said on the order book →
Full Q1 FY26 analysisRanges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Astrazeneca Phar.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Astrazeneca Phar
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Astrazeneca Phar
Quarterly Results
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 285 | 295 | 311 | 306 | 383 | 388 | 408 | 440 | 480 | 526 | 559 | 612 | 579 |
| Expenses + | 225 | 228 | 258 | 291 | 334 | 349 | 355 | 363 | 394 | 445 | 484 | 567 | 518 |
| Operating Profit | 60 | 67 | 53 | 15 | 49 | 38 | 53 | 77 | 86 | 81 | 75 | 45 | 61 |
| OPM % | 21% | 23% | 17% | 5% | 13% | 10% | 13% | 17% | 18% | 15% | 13% | 7% | 11% |
| Other Income + | -32 | 8 | 25 | 10 | 9 | -49 | 8 | -26 | 10 | 11 | 1 | 7 | 5 |
| Interest | 0 | 0 | 0 | 1 | -0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 4 | 9 | 9 | 18 | 17 | 3 | 4 | 6 |
| Profit before tax | 23 | 71 | 73 | 20 | 54 | -15 | 51 | 42 | 78 | 75 | 73 | 47 | 58 |
| Tax % | 26% | 25% | 29% | 23% | 27% | -22% | 25% | 27% | 26% | 25% | 26% | 30% | 23% |
| Net Profit + | 17 | 54 | 52 | 16 | 39 | -12 | 38 | 31 | 58 | 56 | 54 | 33 | 45 |
| EPS in Rs | 6.91 | 21.54 | 20.95 | 6.32 | 15.79 | -4.72 | 15.37 | 12.34 | 23.30 | 22.33 | 21.69 | 13.04 | 17.95 |
Financials of Astrazeneca Phar
Profit & Loss
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 517 | 564 | 544 | 571 | 728 | 832 | 814 | 806 | 1,003 | 1,296 | 1,716 | 2,276 |
| Expenses + | 528 | 547 | 506 | 525 | 657 | 711 | 678 | 719 | 838 | 1,111 | 1,462 | 2,014 |
| Operating Profit | -11 | 16 | 37 | 46 | 71 | 121 | 135 | 86 | 165 | 184 | 254 | 262 |
| OPM % | -2% | 3% | 7% | 8% | 10% | 15% | 17% | 11% | 16% | 14% | 15% | 12% |
| Other Income + | 6 | 7 | 14 | 12 | 16 | 13 | 13 | 15 | -14 | 51 | -56 | 23 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 4 |
| Depreciation | 15 | 17 | 16 | 15 | 15 | 19 | 20 | 17 | 16 | 15 | 40 | 29 |
| Profit before tax | -21 | 6 | 36 | 44 | 73 | 114 | 127 | 83 | 134 | 220 | 156 | 252 |
| Tax % | 0% | 9% | 44% | 41% | 25% | 37% | 27% | 26% | 26% | 26% | 26% | 26% |
| Net Profit + | -21 | 5 | 20 | 26 | 54 | 72 | 93 | 62 | 99 | 162 | 116 | 188 |
| EPS in Rs | -8.34 | 2.10 | 8.02 | 10.36 | 21.78 | 28.88 | 37.32 | 24.64 | 39.72 | 64.60 | 46.30 | 75.01 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 3% | 5% | 41% | 40% | 37% | 69% | 48% |
Financials of Astrazeneca Phar
Balance Sheet
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves | 146 | 151 | 218 | 242 | 296 | 359 | 451 | 506 | 584 | 707 | 765 | 868 |
| Borrowings + | 0 | 0 | 0 | 0 | 0 | 12 | 12 | 9 | 7 | 5 | 36 | 111 |
| Other Liabilities + | 261 | 247 | 193 | 214 | 261 | 330 | 306 | 337 | 389 | 362 | 712 | 1,006 |
| Total Liabilities | 412 | 403 | 415 | 461 | 562 | 706 | 775 | 857 | 985 | 1,078 | 1,518 | 1,989 |
| Fixed Assets + | 101 | 97 | 87 | 75 | 75 | 72 | 81 | 74 | 69 | 67 | 64 | 117 |
| CWIP | 12 | 6 | 5 | 4 | 7 | 24 | 4 | 2 | 1 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 298 | 299 | 324 | 382 | 480 | 611 | 690 | 780 | 915 | 1,011 | 1,454 | 1,872 |
| Total Assets | 412 | 403 | 415 | 461 | 562 | 706 | 775 | 857 | 985 | 1,078 | 1,518 | 1,989 |
Financials of Astrazeneca Phar
Cash Flows
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -46 | 57 | 38 | 9 | 55 | 87 | 105 | 101 | 58 | 28 | 65 | |
| Cash from Investing Activity + | -19 | -4 | 0 | -9 | 4 | -171 | 173 | 5 | 18 | 22 | 31 | |
| Cash from Financing Activity + | 0 | -1 | 0 | 0 | 0 | -6 | -9 | -9 | -24 | -44 | -66 | |
| Net Cash Flow | -64 | 53 | 38 | -1 | 59 | -90 | 269 | 96 | 52 | 5 | 31 | |
| Free Cash Flow | -69 | 48 | 33 | 3 | 37 | 74 | 99 | 94 | 53 | 18 | 64 | |
| CFO/OP | 393% | 365% | 133% | 28% | 126% | 100% | 101% | 146% | 60% | 46% | 51% |
Financials of Astrazeneca Phar
Ratios
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 30 | 54 | 29 | 35 | 40 | 37 | 38 | 39 | 39 | 43 | 39 | 34 |
| Inventory Days | 157 | 141 | 121 | 229 | 186 | 197 | 198 | 164 | 193 | 140 | 208 | 272 |
| Days Payable | 203 | 174 | 184 | 257 | 266 | 251 | 221 | 223 | 231 | 121 | 173 | 207 |
| Cash Conversion Cycle | -16 | 21 | -34 | 7 | -39 | -17 | 15 | -20 | 1 | 62 | 74 | 99 |
| Working Capital Days | -15 | -28 | -36 | -8 | -14 | -16 | -17 | -34 | -18 | 20 | 22 | 50 |
| ROCE % | -13% | 4% | 15% | 19% | 27% | 34% | 30% | 16% | 31% | 31% | 33% | 29% |
Guidance history
How Astrazeneca Phar's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q1 FY26 call → | 20–40% | Flat | Planned | — | Rising |
| Q1 FY25 call → | 20–40% | Down 0–2% | — | — | Rising |
| Q1 FY23 call → | 10–20% | Flat | Planned | — | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
8 out of 100 — Cooling
Over the past year its share price has done worse than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | −32.6% | 19% |
| Last 6 months | −23.3% | 14% |
| Last 3 months | −22.2% | 12% |
The price is 40.2% below its all-time high of ₹10,524.65 (13 Jun 2025). Stocks more than 20% below their peak have their score halved, so 16 became 8.
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Astrazeneca Phar: 0.4 × 19 + 0.4 × 14 + 0.2 × 12 = 16, halved to 8 because the price is more than 20% below its all-time high.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Astrazeneca Phar's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY